A surge of venture capital activity in mid-January signaled renewed investor enthusiasm for startups at the intersection of healthcare and artificial intelligence. Over the course of just two days, several high-profile funding rounds were announced, collectively amounting to nearly $800 million, as investors backed late-stage and growth-phase companies tackling medical innovation and healthcare delivery challenges.
In the Seattle area, Bellevue-based Truveta led the pack with a $320 million fundraising round. The health data startup is building a national genetics and clinical data platform, and this latest round was co-led by pharmaceutical giant Regeneron and genomics leader Illumina, alongside participation from 17 major U.S. health systems. The investment brings Truveta’s valuation to over $1 billion, cementing its position as a key player in the fast-evolving medical data ecosystem. The company’s platform aggregates de-identified patient data to fuel medical research, drug development, and clinical trials, with a growing focus on genetics integration to advance precision medicine.
Further south in Durham, North Carolina, Tune Therapeutics announced a $175 million Series B round. The company specializes in epigenome engineering—using gene modulation instead of gene editing—to develop therapies that regulate gene expression without altering DNA sequences. The funding was led by New Enterprise Associates (NEA), Yosemite, Regeneron Ventures, and the Hevolution Foundation. Tune is among a new wave of startups exploring tunable gene expression technologies as alternatives to traditional CRISPR-based approaches, with the aim of treating chronic conditions more safely and reversibly.
Across the Atlantic but with plans to grow in the U.S., U.K.-based Cera raised $150 million in a combined debt and equity round to accelerate its expansion. The in-home healthcare provider uses AI-powered tools to deliver remote patient monitoring, predictive diagnostics, and digital care coordination for older adults. The investment was co-led by BDT & MSD Partners and Schroders Capital, reflecting global interest in tech-enabled aging and home care solutions.
Meanwhile, in San Francisco, hospital automation startup Qventus secured $85 million in Series D equity funding, plus an additional $20 million in debt financing. The round was led by private equity firm KKR and venture firm Bessemer Venture Partners. Qventus offers AI-powered software to optimize hospital operations, such as scheduling, patient flow, and capacity planning. As hospitals face continued staffing shortages and rising operational costs, demand for automation tools has surged.
Also in California, Clear Labs, a San Carlos-based diagnostics company, raised $30 million in Series D funding. The startup leverages sequencing technology for high-throughput, rapid infectious disease diagnostics and food safety testing. Backers in this round included GV (formerly Google Ventures), Khosla Ventures, and T. Rowe Price. The firm has gained attention for its ability to deploy genomic testing platforms at scale, which has applications in both clinical settings and public health monitoring.
In Boston, Labviva closed a $25 million Series B round. The company operates a procurement platform tailored to the life sciences industry, offering researchers and labs a centralized digital marketplace for sourcing supplies. The round was led by 53 Stations, with participation from B Capital Group. Labviva aims to streamline lab operations by integrating procurement data with scientific workflows, thereby increasing research efficiency.
Rounding out the list, Miami-based First Ascent Biomedical raised $6 million in early-stage funding. The oncology startup uses machine learning to predict patient-specific responses to cancer drugs, with the goal of personalizing cancer treatment strategies. Investors included Vidal Duart Enterprises and accelerator program Techstars. Although smaller in size, the round underscores growing support for AI-powered precision oncology at the seed and early-growth stage.
Together, these investments highlight a strong and diversified appetite among venture capital firms for companies applying advanced technologies to healthcare’s most pressing problems. From AI-driven diagnostics to gene modulation and automation tools for clinical operations, startups are increasingly showing market readiness and scalability potential.
The wave of deals marks a shift from the more cautious investment climate seen throughout much of 2023, suggesting that healthtech and biotech firms with solid traction and unique value propositions are once again commanding significant capital. Many of these companies are operating in niches where policy trends, aging populations, and clinical data availability are converging to create new commercial opportunities.
These mid-January investments, reported by Axios, reflect a broader resurgence in health innovation financing and set a strong tone for venture activity in 2025.
